“New BD” emerges as a higher-margin, connected-care and biologics-delivery pure-play—executing through tariff and regulatory headwinds while the market still prices it like the old conglomerate.
The structural reconfiguration of Becton, Dickinson and Company (BD) as of May 7, 2026, represents a definitive pivot toward a high-margin, pure-play medical technology model. Following the landmark divestiture of its Biosciences and Diagnostic Solutions segments in February 2026 and their subsequent combination with Waters Corporation, the entity now known as "New BD" has emerged with a leaner, more focused operational profile.[1, 2, 3] This metamorphosis is not merely a divestment strategy but a fundamental reimagining of the company’s role in the global healthcare ecosystem, prioritizing connected care, advanced patient monitoring, and the surging biologic drug delivery market.[2, 4]
The historical trajectory of Becton, Dickinson and Company has been characterized by a century-long legacy in medical supplies, yet the 2024–2026 period marks its most radical evolution.[2, 5] By shedding its broad-based healthcare conglomerate identity, BD has repositioned itself to capture value in high-growth, high-margin categories.[2] The completion of the separation of the Biosciences and Diagnostic Solutions business—formerly part of the Life Sciences segment—on February 9, 2026, allowed for a full pivot to this "New BD" strategy.[3, 4]
This structural realignment resulted in the elimination of the legacy Life Sciences segment, leaving the company with four distinct, separately managed segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional.[3, 6] The "New BD" perimeter is designed to maximize shareholder value by focusing on higher "WAMGR" (Weighted Average Market Growth Rate) spaces while leveraging the "BD Excellence" operating model to drive manufacturing productivity and commercial rigor.[1, 7]
| Segment | Core Focus Areas | Key Platforms and Technologies |
|---|---|---|
| Medical Essentials | High-volume clinical consumables | BD Vacutainer, Vascular Access, CentroVena One |
| Connected Care | Infusion and patient monitoring | Alaris Platform, APM (Advanced Patient Monitoring), HemoSphere |
| BioPharma Systems | Specialized drug delivery systems | BD Neopak, GLP-1 delivery infrastructure, Biologics |
| Interventional | Specialty surgery and chronic care | PureWick, Advanced Tissue Regeneration, Revello Stents |
Data synthesized from.[2, 3, 6]
The fiscal second quarter 2026 financial results, released on May 7, 2026, provided the first comprehensive look at the operational momentum of the "New BD" following the Waters transaction. The data indicates broad-based execution that exceeded internal and analyst expectations, prompting an upward revision of full-year earnings guidance.[1, 8]
The company reported total revenue of $\$4.714$ billion, representing a $5.2\%$ increase on a reported basis and a $2.6\%$ increase on a currency-neutral basis.[3] Adjusted diluted earnings per share reached $\$2.90$, surpassing the consensus forecast of $\$2.78$ by $4.32\%$.[1] This performance was particularly notable given the structural headwinds from the divestiture and ongoing macroeconomic pressures.[1, 9]
| Metric | Q2 FY2026 | Q2 FY2025 | Change (Reported) | Change (FXN) |
|---|---|---|---|---|
| Total Revenue | $\$4,714$ Million | $\$4,480$ Million | $5.2\%$ | $2.6\%$ |
| Adjusted Gross Profit | $\$2,579$ Million | $\$2,492$ Million | $3.5\%$ | -- |
| Adjusted Gross Margin | $54.7\%$ | $55.6\%$ | $(90)$ bps | -- |
| Adjusted Operating Income | $\$1,142$ Million | $\$1,133$ Million | $0.8\%$ | -- |
| Adjusted Operating Margin | $24.2\%$ | $25.3\%$ | $(110)$ bps | -- |
| Adjusted Diluted EPS | $\$2.90$ | $\$2.79$ | $3.9\%$ | $1.1\%$ |
Data extracted from.[1, 3]
The contraction in adjusted operating margin to $24.2\%$ was primarily driven by a $160$ basis point headwind from tariffs and shifts in product mix, which were partially offset by $70$ basis points of productivity gains and positive mix contributions from high-growth platforms.[1, 7] Management highlighted that more than $90\%$ of the business delivered mid-single-digit growth, reflecting the resilience of the reorganized portfolio.[1, 3]
The United States remained the dominant market for BD, generating $\$2.917$ billion in revenue for the quarter, a $5.1\%$ increase year-over-year.[3] International revenue totaled $\$1.797$ billion, up $5.5\%$ on a reported basis but down $1.4\%$ on a currency-neutral basis, reflecting the impact of volume-based procurement (VBP) in China and challenging comparisons in certain emerging markets.[3]
| Region | Q2 FY2026 Revenue ($M) | Reported Change | FX-Neutral Change |
|---|---|---|---|
| United States | $\$2,917$ | $5.1\%$ | $5.1\%$ |
| International | $\$1,797$ | $5.5\%$ | $(1.4)\%$ |
| Total BD | $\$4,714$ | $5.2\%$ | $2.6\%$ |
Data derived from.[3]
The "New BD" segment architecture allows for a more granular assessment of the company's competitive advantages in specific clinical and industrial categories.
As the company's largest segment, Medical Essentials recorded $\$1.647$ billion in revenue, reflecting $1.7\%$ currency-neutral growth.[1, 3] This segment is characterized by a "moat" built on scale and an unparalleled global distribution network, producing over $34$ billion medical devices annually.[2, 10]
Within this segment, Medication Delivery Solutions grew $1.4\%$, with market share gains in U.S. Vascular Access Management helping to offset the continued impact of VBP in China.[1] Specimen Management grew $2.5\%$, driven by the adoption of the BD Vacutainer portfolio.[1] A significant innovation catalyst in this segment is the launch of the BD CentroVena One Insertion System, a device that simplifies central line placement and directly addresses the nursing shortage by reducing procedural complexity.[2, 3]
The Connected Care segment, generating $\$1.120$ billion in revenue with $3.2\%$ currency-neutral growth, is the technological vanguard of the company.[1, 3] The integration of the Advanced Patient Monitoring (APM) unit—acquired from Edwards Lifesciences—has positioned BD to lead in "MedTech 3.0".[2, 9]
The APM unit stood out with $12.0\%$ growth in Q2 2026, fueled by the adoption of HemoSphere Alta and Smart Recovery consumables.[1, 7] Management's "Connected Care" strategy aims to build a seamless link from the pharmacy to the bedside, exemplified by the partnership with Wellstar Health System to integrate BD Pyxis Pro and BD Alaris platforms via AI-powered medication management.[3, 11] Despite difficult comparisons in Alaris capital sales, the platform achieved $150$ basis points of market share gain year-to-date, supported by the "largest competitive funnel in history" and zero reported infusion account losses in the quarter.[7]
BioPharma Systems revenue reached $\$590$ million, declining $1.8\%$ on a currency-neutral basis as vaccine-related demand continued to normalize.[1, 3] However, this normalization masks the explosive growth in the Biologics platform, which now accounts for approximately $55\%$ of the segment's revenue.[1, 7]
BD is "hyper-focused" on providing the delivery infrastructure for the GLP-1 market.[7] The company secured two next-generation GLP-1 program wins with leading pharmaceutical companies in the quarter.[1] To support this demand, BD has invested $\$110$ million to establish BD Neopak Glass Prefillable Syringe production in Nebraska, aiming to accelerate the delivery of biologic and GLP-1 drugs while supporting U.S. pharmaceutical reshoring.[4, 9]
The Interventional segment delivered the strongest revenue performance, totaling $\$1.357$ billion, up $5.3\%$ on a currency-neutral basis.[1, 3] This was driven by double-digit expansion in the PureWick portfolio within the Urology & Critical Care unit.[1, 7] The Surgery unit grew $5.5\%$, supported by Infection Prevention and Advanced Tissue Regeneration products.[1] Key regulatory wins, such as the CE Marking for the Revello Vascular Covered Stent and the Liverty TIPS Stent Graft, underscore the segment's focus on high-margin, specialty surgical solutions.[3]
The company's ability to maintain a $25\%$ adjusted operating margin target in fiscal 2026, despite significant tariff and inflationary pressures, is a testament to the "BD Excellence" operating system.[1, 7, 9] This framework drives productivity through manufacturing plant rationalization and commercial rigor.
Management reported approximately $8\%$ gross productivity gains in its manufacturing plants during the second quarter.[1, 7] The company is also executing a $\$200$ million cost-reduction program, with $\$150$ million in run-rate savings already achieved.[1, 7] As of May 2026, the company has simplified its manufacturing footprint to approximately 50 sites, enhancing operational leverage and cash flow generation.[7, 8]
| Metric | Achievement | Strategic Significance |
|---|---|---|
| Gross Productivity | $8\%$ in manufacturing | Offsets tariff and raw material costs |
| Cost-Out Program | $\$150M$ of $\$200M$ target | Funds reinvestment in R&D and M&A |
| Plant Service Levels | Loading Flash…
|
Ensures reliability for critical clinical supplies |
| Manufacturing Sites | $\approx 50$ | Footprint simplification for margin expansion |
Data synthesized from.[1, 7, 8]
BD's strategic transformation is occurring against a backdrop of several transformative macro trends that favor its new, more focused portfolio.
A chronic global shortage of nursing staff has transformed hospital procurement priorities. Healthcare facilities are increasingly viewing BD's automated medication dispensing and infusion systems as essential infrastructure to reduce the manual burden on clinicians.[2, 12] The "Connected Care" strategy directly addresses this "labor gap" by utilizing AI to streamline pharmacy workflows and bedside monitoring.[2]
Demographic shifts in G7 nations continue to drive long-term demand for chronic care interventions. This is particularly evident in the $6.5\%$ growth of the Urology & Critical Care unit and the double-digit success of the PureWick portfolio, as more patients require non-invasive, home-based solutions for incontinence and other chronic conditions.[1, 4, 13]
| Market Segment | 2025 Value ($B) | 2026E Value ($B) | 2030F Value ($B) | CAGR (2026-2030) |
|---|---|---|---|---|
| Infusion Pumps | $\$15.73$ | $\$17.20$ | $\$25.01$ | $9.8\%$ |
| Wearable Pumps | $\$3.50$ | $\$3.70$ | $\$5.90$ (by 2033) | $6.3\%$ |
| GLP-1 Therapeutics | $\$132.00$ | -- | $+\$100B$ growth by 2029 | $33.5\%$ (5-yr) |
Data sourced from.[12, 14, 15, 16, 17]
With the completion of the Waters transaction, BD has refined its capital allocation strategy to prioritize shareholder returns and debt retirement while maintaining a disciplined approach to "tuck-in" M&A.[7]
In the first half of fiscal 2026, BD returned $\$ 2.3$ billion to shareholders, including $\$ 2$ billion through an accelerated share repurchase (ASR) program and $\$ 300$ million in dividends.[1, 7] This aggressive repurchase strategy is based on management’s view that the stock remains undervalued relative to its pure-play medtech peers.[7, 9] The current annualized dividend rate stands at $\$4.20$ per share, marking a 54-year streak of growth.[9, 18]
The company retired $\$2.1$ billion of debt during the second quarter, bringing net leverage to $2.9x$.[3, 7] Management remains committed to a long-term net leverage target of $2.5x$.[7] The retirement of debt is particularly critical given the interest expense guidance of $\$ 600$ to $\$ 620$ million for fiscal 2026.[9]
BD generated $\$1.3$ billion in operating cash flow and $\$1.1$ billion in free cash flow in the first half of fiscal 2026.[1, 7] This represent a significant improvement over the prior year, driven by improved working capital management and inventory efficiency through the BD Excellence program.[1, 7]
Despite strong operational performance, BD faces several regulatory and market-specific risks that could impact its valuation and growth trajectory.
BD continues to manage residual regulatory risks, particularly concerning the Alaris platform. On September 12, 2025, the company expanded a Class I voluntary recall of certain Alaris pump infusion sets due to performance variations that could impact dose accuracy.[19, 20] Furthermore, a voluntary recall was issued for Alaris modules that may have been serviced with legacy bezel kit assemblies manufactured with plastics prone to weakening over time.[21] These recalls have been associated with reports of serious injuries and patient deaths, keeping the platform under intense FDA scrutiny.[19, 21]
The company reported that an FDA warning letter for its El Paso facility led to a temporary hold on ChloraPrep/PurePrep shipments in the United States for additional testing.[8] While management expects this hold to be resolved within three weeks and has reported no patient safety signals, such disruptions highlight the execution risks in a highly regulated manufacturing environment.[8]
China remains a source of uncertainty due to VBP and broader macroeconomic shifts. While China currently represents only approximately $4\%$ of total company revenue, the impact of centralized procurement on categories like Peripheral Intervention continues to be a headwind.[1, 7, 9] Additionally, new compliance mandates in China regarding medical insurance fraud and electronic tracking systems have increased the administrative burden on multinational medical device manufacturers.[22]
Analyst sentiment following the Q2 results has been cautiously optimistic, with many research firms highlighting the "mispricing" of BDX relative to its fundamentals and peer group.[9, 23]
As of May 2026, Becton Dickinson traded at a forward P/E of approximately $23.5x$ to $24.3x$, which is significantly lower than its historical 10-year average of $63.87x$ (though that average is distorted by extreme peaks in 2018).[24, 25, 26] Relative to peers like Stryker ($26x$) or Abbott ($22x$), some analysts argue BD represents an attractive "compounder" opportunity, especially given its
| Analyst Firm | Target Price | Rating | Date |
|---|---|---|---|
| Barclays | $\$202$ | -- | Feb 2026 |
| Citigroup | $\$198$ | Buy | Feb 2026 |
| Jefferies | $\$190$ | Buy | Feb 2026 |
| Evercore | $\$180$ | Outperform | Apr 2026 |
| Goldman Sachs | $\$167$ | Neutral | Apr 2026 |
| TD Cowen | $\$163$ | -- | May 2026 |
| Piper Sandler | $\$159$ | Neutral | Apr 2026 |
| Consensus Median | $\$180 - $\$186 | Hold/Buy Mix | May 2026 |
Data consolidated from.[18, 23, 27, 28]
Institutional ownership remains robust, with over 1,500 total owners.[29] Notable recent activity includes Vanguard Group increasing its stake to $12.85\%$ (36.6 million shares) as of early 2026.[29] However, some institutional investors, such as Auto-Owners Insurance Co and T. Rowe Price, have significantly reduced their positions during the transition year.[27, 28] Insider activity over the last six months has been dominated by sales, with executives Michael Garrison and Michael Feld reporting multiple open-market transactions.[27, 28]
The appointment of Vitor Roque as Executive Vice President and Chief Financial Officer on May 7, 2026, marks the completion of the executive team transition for the "New BD" era.[30] Roque's compensation package, which includes a target annual bonus of $95\%$ of his $\$770,000$ base salary and an annual equity target of $\$3$ million, is structured to incentivize long-term shareholder value creation.[30]
The board nominees approved at the 2026 Annual Meeting represent a diverse array of leadership experience from the medical, financial, and industrial sectors.[31, 32]
| Nominee | Background |
|---|---|
| Thomas E. Polen | Chairman, CEO and President, BD |
| Jeffrey W. Henderson | Former CFO, Cardinal Health Inc. |
| Joanne Waldstreicher, M.D. | Former Chief Medical Officer, Johnson & Johnson |
| Gregory J. Hayes | Former CEO, RTX Corporation |
| Robert L. Huffines | Former Global Chair, Investment Banking, J.P. Morgan |
| Timothy M. Ring | Former Chairman and CEO, C. R. Bard, Inc. |
Data sourced from.[32]
From a technical perspective, BDX has faced a challenging medium-term environment. As of May 5, 2026, the stock was trading below both its 50-day moving average ($\$159.08$) and its 200-day moving average ($\$181.33$), which some technical analysts categorized as a "death cross" structure, indicating a mild downtrend.[18, 33, 34]
The stock's Relative Strength Index (RSI) stood at $43.39$, signaling neutral conditions with a slight bearish bias.[34] However, the $5.7\%$ jump following the Q2 results may indicate a potential breakout from the "falling trend channel" if the price can sustain a move above the $\$154$ resistance level.[28, 35]
The primary catalyst for BD in the late 2026 to 2027 period will be the realization of margin expansion. As the costs associated with the Waters spin-off fade and the Alaris remediation concludes (expected by the end of fiscal 2026), analysts anticipate a significant re-rating of the stock.[2, 7]
Management has reaffirmed its long-term commitment to mid-single-digit revenue growth and double-digit adjusted EPS growth.[7] When tariff impacts normalize, the underlying margin trajectory is projected to reach the $26\%$+ territory.[9] Furthermore, the company aims to reach $\$1$ billion in annual drug delivery revenue by 2030, driven by its leadership in the GLP-1 infrastructure space.[9]
Becton, Dickinson and Company stands at a pivotal crossroads in May 2026. The transition to the "New BD" perimeter has created a leaner, more focused organization that is deeply integrated into the high-growth worlds of AI-driven medication management and biologic drug delivery.[2] The company's fiscal second quarter 2026 results serve as a powerful validation of this strategy, demonstrating that operational excellence and productivity gains can effectively offset significant macroeconomic headwinds.[1, 7]
The combination of a $2.9\%$ dividend yield, an aggressive $\$2$ billion share repurchase program, and a clear path to $26\%$+ operating margins suggests that the current valuation discount may be transitory.[9, 18] For professional stakeholders, the core investment thesis for BD in 2026 rests on the company's transition from a volume-based medical supplier to a value-based MedTech innovator, capable of providing the essential "delivery infrastructure" for the next generation of global healthcare.[2, 9] As the organization moves toward its fiscal 2027 targets, its ability to maintain commercial rigor through the BD Excellence framework will be the definitive factor in its long-term market leadership.
View Becton, Dickinson and Company (BDX) stock page
Loading the interactive version of this report…